We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Athira Pharma, Inc. (ATHA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Athira Pharma, Inc. is a member of our Medical group, which includes 1158 different companies and currently sits at #11 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Athira Pharma, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATHA's full-year earnings has moved 15.8% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ATHA has returned 3.7% so far this year. Meanwhile, stocks in the Medical group have lost about 4.1% on average. This shows that Athira Pharma, Inc. is outperforming its peers so far this year.
HCA Healthcare (HCA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 2.6%.
The consensus estimate for HCA Healthcare's current year EPS has increased 1.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Athira Pharma, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 538 individual companies and currently sits at #155 in the Zacks Industry Rank. On average, this group has lost an average of 11% so far this year, meaning that ATHA is performing better in terms of year-to-date returns.
In contrast, HCA Healthcare falls under the Medical - Hospital industry. Currently, this industry has 6 stocks and is ranked #38. Since the beginning of the year, the industry has moved +4.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Athira Pharma, Inc. and HCA Healthcare as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Athira Pharma, Inc. (ATHA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Athira Pharma, Inc. is a member of our Medical group, which includes 1158 different companies and currently sits at #11 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Athira Pharma, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATHA's full-year earnings has moved 15.8% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ATHA has returned 3.7% so far this year. Meanwhile, stocks in the Medical group have lost about 4.1% on average. This shows that Athira Pharma, Inc. is outperforming its peers so far this year.
HCA Healthcare (HCA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 2.6%.
The consensus estimate for HCA Healthcare's current year EPS has increased 1.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Athira Pharma, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 538 individual companies and currently sits at #155 in the Zacks Industry Rank. On average, this group has lost an average of 11% so far this year, meaning that ATHA is performing better in terms of year-to-date returns.
In contrast, HCA Healthcare falls under the Medical - Hospital industry. Currently, this industry has 6 stocks and is ranked #38. Since the beginning of the year, the industry has moved +4.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Athira Pharma, Inc. and HCA Healthcare as they could maintain their solid performance.